Evidence map›Paper›PMID 40514583›Full record

ArticleMedical oncology (Northwood, London, England)2025

Tumor-derived CXCL5 promotes 5-fluorouracil resistance in colorectal cancer cells via p21 downregulation.

Wanjun Xu, Jianjun Wang, Wencan Han, Jinmin Sun, Xuemei Yang, Xiaomin Li, Dongsheng Pei

Abstract read
PubMed Publisher
In one paragraph

Article in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Wanjun Xu *Department of Pathology, Laboratory of Clinical and Experimental Pathology, National Demonstration Center for Experimental Basic Medical Science Education, School of Basic Medical Sciences, Xuzhou Medical University, Xuzhou, 221004, Jiangsu, China.
Jianjun Wang *Department of Histology and Embryology, Wannan Medical College, Wuhu, 241002, Anhui, China.
Wencan Han *Department of Pathology, Laboratory of Clinical and Experimental Pathology, National Demonstration Center for Experimental Basic Medical Science Education, School of Basic Medical Sciences, Xuzhou Medical University, Xuzhou, 221004, Jiangsu, China.
Jinmin SunDepartment of Pathology, Laboratory of Clinical and Experimental Pathology, National Demonstration Center for Experimental Basic Medical Science Education, School of Basic Medical Sciences, Xuzhou Medical University, Xuzhou, 221004, Jiangsu, China.
Xuemei YangDepartment of Pathology, Laboratory of Clinical and Experimental Pathology, National Demonstration Center for Experimental Basic Medical Science Education, School of Basic Medical Sciences, Xuzhou Medical University, Xuzhou, 221004, Jiangsu, China.
Xiaomin LiDepartment of Pathology, Laboratory of Clinical and Experimental Pathology, National Demonstration Center for Experimental Basic Medical Science Education, School of Basic Medical Sciences, Xuzhou Medical University, Xuzhou, 221004, Jiangsu, China. lxm1980326@sina.com.
Dongsheng PeiDepartment of Pathology, Laboratory of Clinical and Experimental Pathology, National Demonstration Center for Experimental Basic Medical Science Education, School of Basic Medical Sciences, Xuzhou Medical University, Xuzhou, 221004, Jiangsu, China. dspei@xzhmu.edu.cn.

Funding

the Medical Research Project of Jiangsu Provincial Health Commission M2024038the Social Development Projects of Key R&D Programs in Xuzhou Grant KC23247the Suqian Sci&Tech Program Grant KY202304the Suqian Talent Xiongying Plan Project Grant SQXY202436
6 · The paper itself

Abstract

The efficacy of 5-fluorouracil treatment for colorectal cancer (CRC) is substantially compromised by drug resistance, although the underlying mechanisms remain unclear. In this research, we aimed to explore the role and mechanism of action of CXC motif chemokine ligand 5 (CXCL5) in 5-fluorouracil resistance. RNA sequencing was conducted to detect abnormally expressed genes in the 5-fluorouracil-resistant colon cancer cell line, HCT8-5FU. CXCL5 expression in CRC tissues and cell lines was evaluated using RT-qPCR, western blotting, and immunohistochemistry. In vivo and in vitro assays were conducted to evaluate the role of CXCL5 in the promotion of CRC progression. Mass spectrometry and co-immunoprecipitation were employed to investigate the role of CXCL5 in CRC development and 5-fluorouracil resistance. Immunofluorescence and western blot analyses were employed to determine the subcellular localization of CXCL5 and its associated signaling pathways. CXCL5 expression was elevated in both CRC tissues and cell lines. CXCL5 promoted CRC cell growth and resistance to 5-fluorouracil in both in vitro and in vivo settings. Mechanistically, CXCL5 may modulate the MDM2/p53 axis to inhibit p21 by binding to RALY. In this study, CXCL5 accelerated CRC progression and increased CRC cell resistance to 5-fluorouracil via the inhibition of p21 expression. Thus, CXCL5 is a potential target for CRC therapeutic strategies.

Indexed as

Chemokine CXCL5Colorectal NeoplasmsCyclin-Dependent Kinase Inhibitor p21Drug Resistance, NeoplasmFluorouracilAnimalsAntimetabolites, AntineoplasticCell Line, TumorCell ProliferationDown-RegulationFemaleGene Expression Regulation, NeoplasticHumansMaleMiceMice, Inbred BALB CAntimetabolites, AntineoplasticCDKN1A protein, humanChemokine CXCL5CXCL5 protein, humanCyclin-Dependent Kinase Inhibitor p21Fluorouracil5-fluorouracilColorectal cancerCXCL5p21

Identifiers

PMID40514583

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.